Candel Therapeutics Inc (CADL) Cotización

CADL...$13.19...🥳...Watch for All Time highs here...

georgie18

Member Level
Re: georgie18 post# 32234

Thursday, February 20, 2025 10:01:31 AM

Post#
32302
of 32319
CADL...$12.33...🥳...Another Runner on the Cup N Handle Breakout...

georgie18

Member Level
Re: georgie18 post# 178

Wednesday, February 19, 2025 11:56:55 AM

Post#
179
of 179
CADL...$10.60...🥳...Cup N Handle Breakout....Off my $7 range Alert...

georgie18

Member Level
Re: georgie18 post# 30792

Tuesday, February 18, 2025 9:52:58 AM

Post#
32134
of 32233
CADL...$10.07...🥳...Cup N Handle in play here...Watch for $14.85 Breakout...imo...we shall see...

georgie18

Member Level
Re: georgie18 post# 160

Wednesday, January 22, 2025 10:41:18 AM

Post#
165
of 177
CADL...Added a load under $7...🥳... Cup N Handle Pattern ...Looking for Triple Top Breakout at $14.85 Range... https://schrts.co/spDmKkki

georgie18

Member Level
Re: None

Thursday, January 16, 2025 3:45:04 PM

Post#
671612
of 671947
CADL...$7.81...🥳...50/100 Ready to Cross the 200... https://schrts.co/nPxatndN

On track to report updated overall survival data for CAN-2409 from phase 2a clinical trials in pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC), expected in Q1 2025
Preparations for Biologics License Application (BLA) for CAN-2409 in prostate cancer underway, with submission expected in Q4 2026
The Company intends to present phase 3 clinical trial data from CAN-2409 in prostate cancer at upcoming scientific conferences
On track to report overall survival data in patients with recurrent high-grade glioma (rHGG) from ongoing phase 1b trial evaluating multiple doses of CAN-3110, expected in Q4 2025
The Company expects that its cash and cash equivalents of approximately $103M (unaudited) as of December 31, 2024, will be sufficient to fund its current operating plan into Q1 of 2027
NEEDHAM, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today highlighted recent successes across the Company's viral immunotherapy portfolio and provided an update on the Company’s cash position and upcoming 2025 milestones.

Eventually will break to all time highs...Look at the cHart I posted...🥳

Where is it stopping?

CADL...$12.33...🥳...Another Runner on the Cup N Handle Breakout...

georgie18

Member Level
Re: georgie18 post# 178

Wednesday, February 19, 2025 11:56:55 AM

Post#
179
of 179
CADL...$10.60...🥳...Cup N Handle Breakout....Off my $7 range Alert...

georgie18

Member Level
Re: georgie18 post# 30792

Tuesday, February 18, 2025 9:52:58 AM

Post#
32134
of 32233
CADL...$10.07...🥳...Cup N Handle in play here...Watch for $14.85 Breakout...imo...we shall see...

georgie18

Member Level
Re: georgie18 post# 160

Wednesday, January 22, 2025 10:41:18 AM

Post#
165
of 177
CADL...Added a load under $7...🥳... Cup N Handle Pattern ...Looking for Triple Top Breakout at $14.85 Range... https://schrts.co/spDmKkki

georgie18

Member Level
Re: None

Thursday, January 16, 2025 3:45:04 PM

Post#
671612
of 671947
CADL...$7.81...🥳...50/100 Ready to Cross the 200... https://schrts.co/nPxatndN

On track to report updated overall survival data for CAN-2409 from phase 2a clinical trials in pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC), expected in Q1 2025
Preparations for Biologics License Application (BLA) for CAN-2409 in prostate cancer underway, with submission expected in Q4 2026
The Company intends to present phase 3 clinical trial data from CAN-2409 in prostate cancer at upcoming scientific conferences
On track to report overall survival data in patients with recurrent high-grade glioma (rHGG) from ongoing phase 1b trial evaluating multiple doses of CAN-3110, expected in Q4 2025
The Company expects that its cash and cash equivalents of approximately $103M (unaudited) as of December 31, 2024, will be sufficient to fund its current operating plan into Q1 of 2027
NEEDHAM, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today highlighted recent successes across the Company's viral immunotherapy portfolio and provided an update on the Company’s cash position and upcoming 2025 milestones.

CADL...$10.60...🥳...Cup N Handle Breakout....Off my $7 range Alert...

georgie18

Member Level
Re: georgie18 post# 30792

Tuesday, February 18, 2025 9:52:58 AM

Post#
32134
of 32233
CADL...$10.07...🥳...Cup N Handle in play here...Watch for $14.85 Breakout...imo...we shall see...

georgie18

Member Level
Re: georgie18 post# 160

Wednesday, January 22, 2025 10:41:18 AM

Post#
165
of 177
CADL...Added a load under $7...🥳... Cup N Handle Pattern ...Looking for Triple Top Breakout at $14.85 Range... https://schrts.co/spDmKkki

georgie18

Member Level
Re: None

Thursday, January 16, 2025 3:45:04 PM

Post#
671612
of 671947
CADL...$7.81...🥳...50/100 Ready to Cross the 200... https://schrts.co/nPxatndN

On track to report updated overall survival data for CAN-2409 from phase 2a clinical trials in pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC), expected in Q1 2025
Preparations for Biologics License Application (BLA) for CAN-2409 in prostate cancer underway, with submission expected in Q4 2026
The Company intends to present phase 3 clinical trial data from CAN-2409 in prostate cancer at upcoming scientific conferences
On track to report overall survival data in patients with recurrent high-grade glioma (rHGG) from ongoing phase 1b trial evaluating multiple doses of CAN-3110, expected in Q4 2025
The Company expects that its cash and cash equivalents of approximately $103M (unaudited) as of December 31, 2024, will be sufficient to fund its current operating plan into Q1 of 2027
NEEDHAM, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today highlighted recent successes across the Company's viral immunotherapy portfolio and provided an update on the Company’s cash position and upcoming 2025 milestones.

CADL...$10.07...🥳...Cup N Handle in play here...Watch for $14.85 Breakout...imo...we shall see...

georgie18

Member Level
Re: georgie18 post# 160

Wednesday, January 22, 2025 10:41:18 AM

Post#
165
of 177
CADL...Added a load under $7...🥳... Cup N Handle Pattern ...Looking for Triple Top Breakout at $14.85 Range... https://schrts.co/spDmKkki

georgie18

Member Level
Re: None

Thursday, January 16, 2025 3:45:04 PM

Post#
671612
of 671947
CADL...$7.81...🥳...50/100 Ready to Cross the 200... https://schrts.co/nPxatndN

On track to report updated overall survival data for CAN-2409 from phase 2a clinical trials in pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC), expected in Q1 2025
Preparations for Biologics License Application (BLA) for CAN-2409 in prostate cancer underway, with submission expected in Q4 2026
The Company intends to present phase 3 clinical trial data from CAN-2409 in prostate cancer at upcoming scientific conferences
On track to report overall survival data in patients with recurrent high-grade glioma (rHGG) from ongoing phase 1b trial evaluating multiple doses of CAN-3110, expected in Q4 2025
The Company expects that its cash and cash equivalents of approximately $103M (unaudited) as of December 31, 2024, will be sufficient to fund its current operating plan into Q1 of 2027
NEEDHAM, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today highlighted recent successes across the Company's viral immunotherapy portfolio and provided an update on the Company’s cash position and upcoming 2025 milestones.

13g filing lots of insider buying

CADL...$9.21...🥳

georgie18

Member Level
Re: georgie18 post# 673379

Friday, February 14, 2025 9:37:47 AM

Post#
674437
of 674573
CADL...$9.00...🥳...Been a nice easy mover...

georgie18

Member Level
Re: georgie18 post# 31532

Wednesday, February 05, 2025 10:22:33 AM

Post#
31578
of 32051
CADL...$8.07...🥳...moving beautifully...

georgie18

Member Level
Re: georgie18 post# 673244

Tuesday, February 04, 2025 3:06:34 PM

Post#
673314
of 673377
CADL...$7.86...🥳

georgie18

Member Level
Re: georgie18 post# 31467

Tuesday, February 04, 2025 11:00:49 AM

Post#
31487
of 31531
CADL...$7.55...🥳...ANYBODY PAYING ATTENTION HERE...

georgie18

Member Level
Re: georgie18 post# 673062

Tuesday, February 04, 2025 9:43:19 AM

Post#
673223
of 673243
CADL...$7.38...🥳...Beauty move as price catches up to the News...

georgie18

Member Level
Re: georgie18 post# 31276

Saturday, February 01, 2025 2:12:48 PM

Post#
31345
of 31466
CADL...$7.07...🥳...Bullish Engulfing Candle Reversal signal...50/200 Crossed 100/200 ready to cross...Been loading under $7...Looking for Break/Hold of $14.85 and a run at $18 Record Highs...imo...we shall see...The price will catch up to the News...

georgie18

Member Level
Re: georgie18 post# 672206

Friday, January 31, 2025 10:28:50 AM

Post#
672943
of 673062
CADL...$7.12...This price will soon catch up to the news...🥳Been loading under $7...

georgie18

Member Level
Re: georgie18 post# 30885

Thursday, January 23, 2025 3:25:24 PM

Post#
30907
of 31275
CADL...$7.18...Hit $7.26...Hod...🥳

georgie18

Member Level
Re: georgie18 post# 671947

Thursday, January 23, 2025 2:03:43 PM

Post#
672171
of 672205
CADL...$7.07...🥳...HOD...Off the $6.60 range dip...

georgie18

Member Level
Re: tw0122 post# 30782

Wednesday, January 22, 2025 4:45:28 PM

Post#
30792
of 30884
CADL...Added a load under $7...🥳... Cup N Handle Pattern ...Looking for Triple Top Breakout at $14.85 Range... https://schrts.co/spDmKkki

georgie18

Member Level
Re: None

Thursday, January 16, 2025 3:45:04 PM

Post#
671612
of 671947
CADL...$7.81...🥳...50/100 Ready to Cross the 200... https://schrts.co/nPxatndN

On track to report updated overall survival data for CAN-2409 from phase 2a clinical trials in pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC), expected in Q1 2025
Preparations for Biologics License Application (BLA) for CAN-2409 in prostate cancer underway, with submission expected in Q4 2026
The Company intends to present phase 3 clinical trial data from CAN-2409 in prostate cancer at upcoming scientific conferences
On track to report overall survival data in patients with recurrent high-grade glioma (rHGG) from ongoing phase 1b trial evaluating multiple doses of CAN-3110, expected in Q4 2025
The Company expects that its cash and cash equivalents of approximately $103M (unaudited) as of December 31, 2024, will be sufficient to fund its current operating plan into Q1 of 2027
NEEDHAM, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today highlighted recent successes across the Company's viral immunotherapy portfolio and provided an update on the Company’s cash position and upcoming 2025 milestones.

CADL skidaddle super action

CADL...$9.00...🥳...Been a nice easy mover...

georgie18

Member Level
Re: georgie18 post# 31532

Wednesday, February 05, 2025 10:22:33 AM

Post#
31578
of 32051
CADL...$8.07...🥳...moving beautifully...

georgie18

Member Level
Re: georgie18 post# 673244

Tuesday, February 04, 2025 3:06:34 PM

Post#
673314
of 673377
CADL...$7.86...🥳

georgie18

Member Level
Re: georgie18 post# 31467

Tuesday, February 04, 2025 11:00:49 AM

Post#
31487
of 31531
CADL...$7.55...🥳...ANYBODY PAYING ATTENTION HERE...

georgie18

Member Level
Re: georgie18 post# 673062

Tuesday, February 04, 2025 9:43:19 AM

Post#
673223
of 673243
CADL...$7.38...🥳...Beauty move as price catches up to the News...

georgie18

Member Level
Re: georgie18 post# 31276

Saturday, February 01, 2025 2:12:48 PM

Post#
31345
of 31466
CADL...$7.07...🥳...Bullish Engulfing Candle Reversal signal...50/200 Crossed 100/200 ready to cross...Been loading under $7...Looking for Break/Hold of $14.85 and a run at $18 Record Highs...imo...we shall see...The price will catch up to the News...

georgie18

Member Level
Re: georgie18 post# 672206

Friday, January 31, 2025 10:28:50 AM

Post#
672943
of 673062
CADL...$7.12...This price will soon catch up to the news...🥳Been loading under $7...

georgie18

Member Level
Re: georgie18 post# 30885

Thursday, January 23, 2025 3:25:24 PM

Post#
30907
of 31275
CADL...$7.18...Hit $7.26...Hod...🥳

georgie18

Member Level
Re: georgie18 post# 671947

Thursday, January 23, 2025 2:03:43 PM

Post#
672171
of 672205
CADL...$7.07...🥳...HOD...Off the $6.60 range dip...

georgie18

Member Level
Re: tw0122 post# 30782

Wednesday, January 22, 2025 4:45:28 PM

Post#
30792
of 30884
CADL...Added a load under $7...🥳... Cup N Handle Pattern ...Looking for Triple Top Breakout at $14.85 Range... https://schrts.co/spDmKkki

georgie18

Member Level
Re: None

Thursday, January 16, 2025 3:45:04 PM

Post#
671612
of 671947
CADL...$7.81...🥳...50/100 Ready to Cross the 200... https://schrts.co/nPxatndN

On track to report updated overall survival data for CAN-2409 from phase 2a clinical trials in pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC), expected in Q1 2025
Preparations for Biologics License Application (BLA) for CAN-2409 in prostate cancer underway, with submission expected in Q4 2026
The Company intends to present phase 3 clinical trial data from CAN-2409 in prostate cancer at upcoming scientific conferences
On track to report overall survival data in patients with recurrent high-grade glioma (rHGG) from ongoing phase 1b trial evaluating multiple doses of CAN-3110, expected in Q4 2025
The Company expects that its cash and cash equivalents of approximately $103M (unaudited) as of December 31, 2024, will be sufficient to fund its current operating plan into Q1 of 2027
NEEDHAM, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today highlighted recent successes across the Company's viral immunotherapy portfolio and provided an update on the Company’s cash position and upcoming 2025 milestones.

CADL...$8.07...🥳...moving beautifully...

georgie18

Member Level
Re: georgie18 post# 673244

Tuesday, February 04, 2025 3:06:34 PM

Post#
673314
of 673377
CADL...$7.86...🥳

georgie18

Member Level
Re: georgie18 post# 31467

Tuesday, February 04, 2025 11:00:49 AM

Post#
31487
of 31531
CADL...$7.55...🥳...ANYBODY PAYING ATTENTION HERE...

georgie18

Member Level
Re: georgie18 post# 673062

Tuesday, February 04, 2025 9:43:19 AM

Post#
673223
of 673243
CADL...$7.38...🥳...Beauty move as price catches up to the News...

georgie18

Member Level
Re: georgie18 post# 31276

Saturday, February 01, 2025 2:12:48 PM

Post#
31345
of 31466
CADL...$7.07...🥳...Bullish Engulfing Candle Reversal signal...50/200 Crossed 100/200 ready to cross...Been loading under $7...Looking for Break/Hold of $14.85 and a run at $18 Record Highs...imo...we shall see...The price will catch up to the News...

georgie18

Member Level
Re: georgie18 post# 672206

Friday, January 31, 2025 10:28:50 AM

Post#
672943
of 673062
CADL...$7.12...This price will soon catch up to the news...🥳Been loading under $7...

georgie18

Member Level
Re: georgie18 post# 30885

Thursday, January 23, 2025 3:25:24 PM

Post#
30907
of 31275
CADL...$7.18...Hit $7.26...Hod...🥳

georgie18

Member Level
Re: georgie18 post# 671947

Thursday, January 23, 2025 2:03:43 PM

Post#
672171
of 672205
CADL...$7.07...🥳...HOD...Off the $6.60 range dip...

georgie18

Member Level
Re: tw0122 post# 30782

Wednesday, January 22, 2025 4:45:28 PM

Post#
30792
of 30884
CADL...Added a load under $7...🥳... Cup N Handle Pattern ...Looking for Triple Top Breakout at $14.85 Range... https://schrts.co/spDmKkki

georgie18

Member Level
Re: None

Thursday, January 16, 2025 3:45:04 PM

Post#
671612
of 671947
CADL...$7.81...🥳...50/100 Ready to Cross the 200... https://schrts.co/nPxatndN

On track to report updated overall survival data for CAN-2409 from phase 2a clinical trials in pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC), expected in Q1 2025
Preparations for Biologics License Application (BLA) for CAN-2409 in prostate cancer underway, with submission expected in Q4 2026
The Company intends to present phase 3 clinical trial data from CAN-2409 in prostate cancer at upcoming scientific conferences
On track to report overall survival data in patients with recurrent high-grade glioma (rHGG) from ongoing phase 1b trial evaluating multiple doses of CAN-3110, expected in Q4 2025
The Company expects that its cash and cash equivalents of approximately $103M (unaudited) as of December 31, 2024, will be sufficient to fund its current operating plan into Q1 of 2027
NEEDHAM, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today highlighted recent successes across the Company's viral immunotherapy portfolio and provided an update on the Company’s cash position and upcoming 2025 milestones.

CADL...$7.86...🥳

georgie18

Member Level
Re: georgie18 post# 31467

Tuesday, February 04, 2025 11:00:49 AM

Post#
31487
of 31531
CADL...$7.55...🥳...ANYBODY PAYING ATTENTION HERE...

georgie18

Member Level
Re: georgie18 post# 673062

Tuesday, February 04, 2025 9:43:19 AM

Post#
673223
of 673243
CADL...$7.38...🥳...Beauty move as price catches up to the News...

georgie18

Member Level
Re: georgie18 post# 31276

Saturday, February 01, 2025 2:12:48 PM

Post#
31345
of 31466
CADL...$7.07...🥳...Bullish Engulfing Candle Reversal signal...50/200 Crossed 100/200 ready to cross...Been loading under $7...Looking for Break/Hold of $14.85 and a run at $18 Record Highs...imo...we shall see...The price will catch up to the News...

georgie18

Member Level
Re: georgie18 post# 672206

Friday, January 31, 2025 10:28:50 AM

Post#
672943
of 673062
CADL...$7.12...This price will soon catch up to the news...🥳Been loading under $7...

georgie18

Member Level
Re: georgie18 post# 30885

Thursday, January 23, 2025 3:25:24 PM

Post#
30907
of 31275
CADL...$7.18...Hit $7.26...Hod...🥳

georgie18

Member Level
Re: georgie18 post# 671947

Thursday, January 23, 2025 2:03:43 PM

Post#
672171
of 672205
CADL...$7.07...🥳...HOD...Off the $6.60 range dip...

georgie18

Member Level
Re: tw0122 post# 30782

Wednesday, January 22, 2025 4:45:28 PM

Post#
30792
of 30884
CADL...Added a load under $7...🥳... Cup N Handle Pattern ...Looking for Triple Top Breakout at $14.85 Range... https://schrts.co/spDmKkki

georgie18

Member Level
Re: None

Thursday, January 16, 2025 3:45:04 PM

Post#
671612
of 671947
CADL...$7.81...🥳...50/100 Ready to Cross the 200... https://schrts.co/nPxatndN

On track to report updated overall survival data for CAN-2409 from phase 2a clinical trials in pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC), expected in Q1 2025
Preparations for Biologics License Application (BLA) for CAN-2409 in prostate cancer underway, with submission expected in Q4 2026
The Company intends to present phase 3 clinical trial data from CAN-2409 in prostate cancer at upcoming scientific conferences
On track to report overall survival data in patients with recurrent high-grade glioma (rHGG) from ongoing phase 1b trial evaluating multiple doses of CAN-3110, expected in Q4 2025
The Company expects that its cash and cash equivalents of approximately $103M (unaudited) as of December 31, 2024, will be sufficient to fund its current operating plan into Q1 of 2027
NEEDHAM, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today highlighted recent successes across the Company's viral immunotherapy portfolio and provided an update on the Company’s cash position and upcoming 2025 milestones.

CADL...$7.55...🥳...ANYBODY PAYING ATTENTION HERE...

georgie18

Member Level
Re: georgie18 post# 673062

Tuesday, February 04, 2025 9:43:19 AM

Post#
673223
of 673243
CADL...$7.38...🥳...Beauty move as price catches up to the News...

georgie18

Member Level
Re: georgie18 post# 31276

Saturday, February 01, 2025 2:12:48 PM

Post#
31345
of 31466
CADL...$7.07...🥳...Bullish Engulfing Candle Reversal signal...50/200 Crossed 100/200 ready to cross...Been loading under $7...Looking for Break/Hold of $14.85 and a run at $18 Record Highs...imo...we shall see...The price will catch up to the News...

georgie18

Member Level
Re: georgie18 post# 672206

Friday, January 31, 2025 10:28:50 AM

Post#
672943
of 673062
CADL...$7.12...This price will soon catch up to the news...🥳Been loading under $7...

georgie18

Member Level
Re: georgie18 post# 30885

Thursday, January 23, 2025 3:25:24 PM

Post#
30907
of 31275
CADL...$7.18...Hit $7.26...Hod...🥳

georgie18

Member Level
Re: georgie18 post# 671947

Thursday, January 23, 2025 2:03:43 PM

Post#
672171
of 672205
CADL...$7.07...🥳...HOD...Off the $6.60 range dip...

georgie18

Member Level
Re: tw0122 post# 30782

Wednesday, January 22, 2025 4:45:28 PM

Post#
30792
of 30884
CADL...Added a load under $7...🥳... Cup N Handle Pattern ...Looking for Triple Top Breakout at $14.85 Range... https://schrts.co/spDmKkki

georgie18

Member Level
Re: None

Thursday, January 16, 2025 3:45:04 PM

Post#
671612
of 671947
CADL...$7.81...🥳...50/100 Ready to Cross the 200... https://schrts.co/nPxatndN

On track to report updated overall survival data for CAN-2409 from phase 2a clinical trials in pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC), expected in Q1 2025
Preparations for Biologics License Application (BLA) for CAN-2409 in prostate cancer underway, with submission expected in Q4 2026
The Company intends to present phase 3 clinical trial data from CAN-2409 in prostate cancer at upcoming scientific conferences
On track to report overall survival data in patients with recurrent high-grade glioma (rHGG) from ongoing phase 1b trial evaluating multiple doses of CAN-3110, expected in Q4 2025
The Company expects that its cash and cash equivalents of approximately $103M (unaudited) as of December 31, 2024, will be sufficient to fund its current operating plan into Q1 of 2027
NEEDHAM, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today highlighted recent successes across the Company's viral immunotherapy portfolio and provided an update on the Company’s cash position and upcoming 2025 milestones.

CADL...$7.38...🥳...Beauty move as price catches up to the News...

georgie18

Member Level
Re: georgie18 post# 31276

Saturday, February 01, 2025 2:12:48 PM

Post#
31345
of 31466
CADL...$7.07...🥳...Bullish Engulfing Candle Reversal signal...50/200 Crossed 100/200 ready to cross...Been loading under $7...Looking for Break/Hold of $14.85 and a run at $18 Record Highs...imo...we shall see...The price will catch up to the News...

georgie18

Member Level
Re: georgie18 post# 672206

Friday, January 31, 2025 10:28:50 AM

Post#
672943
of 673062
CADL...$7.12...This price will soon catch up to the news...🥳Been loading under $7...

georgie18

Member Level
Re: georgie18 post# 30885

Thursday, January 23, 2025 3:25:24 PM

Post#
30907
of 31275
CADL...$7.18...Hit $7.26...Hod...🥳

georgie18

Member Level
Re: georgie18 post# 671947

Thursday, January 23, 2025 2:03:43 PM

Post#
672171
of 672205
CADL...$7.07...🥳...HOD...Off the $6.60 range dip...

georgie18

Member Level
Re: tw0122 post# 30782

Wednesday, January 22, 2025 4:45:28 PM

Post#
30792
of 30884
CADL...Added a load under $7...🥳... Cup N Handle Pattern ...Looking for Triple Top Breakout at $14.85 Range... https://schrts.co/spDmKkki

georgie18

Member Level
Re: None

Thursday, January 16, 2025 3:45:04 PM

Post#
671612
of 671947
CADL...$7.81...🥳...50/100 Ready to Cross the 200... https://schrts.co/nPxatndN

On track to report updated overall survival data for CAN-2409 from phase 2a clinical trials in pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC), expected in Q1 2025
Preparations for Biologics License Application (BLA) for CAN-2409 in prostate cancer underway, with submission expected in Q4 2026
The Company intends to present phase 3 clinical trial data from CAN-2409 in prostate cancer at upcoming scientific conferences
On track to report overall survival data in patients with recurrent high-grade glioma (rHGG) from ongoing phase 1b trial evaluating multiple doses of CAN-3110, expected in Q4 2025
The Company expects that its cash and cash equivalents of approximately $103M (unaudited) as of December 31, 2024, will be sufficient to fund its current operating plan into Q1 of 2027
NEEDHAM, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today highlighted recent successes across the Company's viral immunotherapy portfolio and provided an update on the Company’s cash position and upcoming 2025 milestones.

CADL...$7.07...🥳...Bullish Engulfing Candle Reversal signal...50/200 Crossed 100/200 ready to cross...Been loading under $7...Looking for Break/Hold of $14.85 and a run at $18 Record Highs...imo...we shall see...The price will catch up to the News...

georgie18

Member Level
Re: georgie18 post# 672206

Friday, January 31, 2025 10:28:50 AM

Post#
672943
of 673062
CADL...$7.12...This price will soon catch up to the news...🥳Been loading under $7...

georgie18

Member Level
Re: georgie18 post# 30885

Thursday, January 23, 2025 3:25:24 PM

Post#
30907
of 31275
CADL...$7.18...Hit $7.26...Hod...🥳

georgie18

Member Level
Re: georgie18 post# 671947

Thursday, January 23, 2025 2:03:43 PM

Post#
672171
of 672205
CADL...$7.07...🥳...HOD...Off the $6.60 range dip...

georgie18

Member Level
Re: tw0122 post# 30782

Wednesday, January 22, 2025 4:45:28 PM

Post#
30792
of 30884
CADL...Added a load under $7...🥳... Cup N Handle Pattern ...Looking for Triple Top Breakout at $14.85 Range... https://schrts.co/spDmKkki

georgie18

Member Level
Re: None

Thursday, January 16, 2025 3:45:04 PM

Post#
671612
of 671947
CADL...$7.81...🥳...50/100 Ready to Cross the 200... https://schrts.co/nPxatndN

On track to report updated overall survival data for CAN-2409 from phase 2a clinical trials in pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC), expected in Q1 2025
Preparations for Biologics License Application (BLA) for CAN-2409 in prostate cancer underway, with submission expected in Q4 2026
The Company intends to present phase 3 clinical trial data from CAN-2409 in prostate cancer at upcoming scientific conferences
On track to report overall survival data in patients with recurrent high-grade glioma (rHGG) from ongoing phase 1b trial evaluating multiple doses of CAN-3110, expected in Q4 2025
The Company expects that its cash and cash equivalents of approximately $103M (unaudited) as of December 31, 2024, will be sufficient to fund its current operating plan into Q1 of 2027
NEEDHAM, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today highlighted recent successes across the Company's viral immunotherapy portfolio and provided an update on the Company’s cash position and upcoming 2025 milestones.

CADL...$7.12...This price will soon catch up to the news...🥳Been loading under $7...

georgie18

Member Level
Re: georgie18 post# 30885

Thursday, January 23, 2025 3:25:24 PM

Post#
30907
of 31275
CADL...$7.18...Hit $7.26...Hod...🥳

georgie18

Member Level
Re: georgie18 post# 671947

Thursday, January 23, 2025 2:03:43 PM

Post#
672171
of 672205
CADL...$7.07...🥳...HOD...Off the $6.60 range dip...

georgie18

Member Level
Re: tw0122 post# 30782

Wednesday, January 22, 2025 4:45:28 PM

Post#
30792
of 30884
CADL...Added a load under $7...🥳... Cup N Handle Pattern ...Looking for Triple Top Breakout at $14.85 Range... https://schrts.co/spDmKkki

georgie18

Member Level
Re: None

Thursday, January 16, 2025 3:45:04 PM

Post#
671612
of 671947
CADL...$7.81...🥳...50/100 Ready to Cross the 200... https://schrts.co/nPxatndN

On track to report updated overall survival data for CAN-2409 from phase 2a clinical trials in pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC), expected in Q1 2025
Preparations for Biologics License Application (BLA) for CAN-2409 in prostate cancer underway, with submission expected in Q4 2026
The Company intends to present phase 3 clinical trial data from CAN-2409 in prostate cancer at upcoming scientific conferences
On track to report overall survival data in patients with recurrent high-grade glioma (rHGG) from ongoing phase 1b trial evaluating multiple doses of CAN-3110, expected in Q4 2025
The Company expects that its cash and cash equivalents of approximately $103M (unaudited) as of December 31, 2024, will be sufficient to fund its current operating plan into Q1 of 2027
NEEDHAM, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today highlighted recent successes across the Company's viral immunotherapy portfolio and provided an update on the Company’s cash position and upcoming 2025 milestones.

CADL...$7.18...Hit $7.26...Hod...🥳

georgie18

Member Level
Re: georgie18 post# 671947

Thursday, January 23, 2025 2:03:43 PM

Post#
672171
of 672205
CADL...$7.07...🥳...HOD...Off the $6.60 range dip...

georgie18

Member Level
Re: tw0122 post# 30782

Wednesday, January 22, 2025 4:45:28 PM

Post#
30792
of 30884
CADL...Added a load under $7...🥳... Cup N Handle Pattern ...Looking for Triple Top Breakout at $14.85 Range... https://schrts.co/spDmKkki

georgie18

Member Level
Re: None

Thursday, January 16, 2025 3:45:04 PM

Post#
671612
of 671947
CADL...$7.81...🥳...50/100 Ready to Cross the 200... https://schrts.co/nPxatndN

On track to report updated overall survival data for CAN-2409 from phase 2a clinical trials in pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC), expected in Q1 2025
Preparations for Biologics License Application (BLA) for CAN-2409 in prostate cancer underway, with submission expected in Q4 2026
The Company intends to present phase 3 clinical trial data from CAN-2409 in prostate cancer at upcoming scientific conferences
On track to report overall survival data in patients with recurrent high-grade glioma (rHGG) from ongoing phase 1b trial evaluating multiple doses of CAN-3110, expected in Q4 2025
The Company expects that its cash and cash equivalents of approximately $103M (unaudited) as of December 31, 2024, will be sufficient to fund its current operating plan into Q1 of 2027
NEEDHAM, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today highlighted recent successes across the Company's viral immunotherapy portfolio and provided an update on the Company’s cash position and upcoming 2025 milestones.

CADL...$7.07...🥳...HOD...Off the $6.60 range dip...

georgie18

Member Level
Re: tw0122 post# 30782

Wednesday, January 22, 2025 4:45:28 PM

Post#
30792
of 30884
CADL...Added a load under $7...🥳... Cup N Handle Pattern ...Looking for Triple Top Breakout at $14.85 Range... https://schrts.co/spDmKkki

georgie18

Member Level
Re: None

Thursday, January 16, 2025 3:45:04 PM

Post#
671612
of 671947
CADL...$7.81...🥳...50/100 Ready to Cross the 200... https://schrts.co/nPxatndN

On track to report updated overall survival data for CAN-2409 from phase 2a clinical trials in pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC), expected in Q1 2025
Preparations for Biologics License Application (BLA) for CAN-2409 in prostate cancer underway, with submission expected in Q4 2026
The Company intends to present phase 3 clinical trial data from CAN-2409 in prostate cancer at upcoming scientific conferences
On track to report overall survival data in patients with recurrent high-grade glioma (rHGG) from ongoing phase 1b trial evaluating multiple doses of CAN-3110, expected in Q4 2025
The Company expects that its cash and cash equivalents of approximately $103M (unaudited) as of December 31, 2024, will be sufficient to fund its current operating plan into Q1 of 2027
NEEDHAM, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today highlighted recent successes across the Company's viral immunotherapy portfolio and provided an update on the Company’s cash position and upcoming 2025 milestones.

CADL...Added a load under $7...🥳... Cup N Handle Pattern ...Looking for Triple Top Breakout at $14.85 Range... https://schrts.co/spDmKkki

georgie18

Member Level
Re: None

Thursday, January 16, 2025 3:45:04 PM

Post#
671612
of 671947
CADL...$7.81...🥳...50/100 Ready to Cross the 200... https://schrts.co/nPxatndN

On track to report updated overall survival data for CAN-2409 from phase 2a clinical trials in pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC), expected in Q1 2025
Preparations for Biologics License Application (BLA) for CAN-2409 in prostate cancer underway, with submission expected in Q4 2026
The Company intends to present phase 3 clinical trial data from CAN-2409 in prostate cancer at upcoming scientific conferences
On track to report overall survival data in patients with recurrent high-grade glioma (rHGG) from ongoing phase 1b trial evaluating multiple doses of CAN-3110, expected in Q4 2025
The Company expects that its cash and cash equivalents of approximately $103M (unaudited) as of December 31, 2024, will be sufficient to fund its current operating plan into Q1 of 2027
NEEDHAM, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today highlighted recent successes across the Company's viral immunotherapy portfolio and provided an update on the Company’s cash position and upcoming 2025 milestones.

As I said, I should have known...

Thanks again.

BP = Big Pharma

Sorry for my ignorance, but what is "BP"? Sorry if it's mentioned elsewhere on this board and I missed it.

Agreed, late 2026 is not a fun timeline, but hoping they come out with additional info before then.

And although they all have their "small window" to sell to earn their compensation, never pleasant to see that as well.

Little disappointed with the very late 2026 submission date.  Heard someone say it was because they had to nail down the manufacturing first.  Somehow they would be better off selling to BP and be done with it.  Although very happy with prostate results, just getting a little worried about the 2 readouts this qtr as pancreatic is a bitch. 

CADL...$7.81...🥳...50/100 Ready to Cross the 200... https://schrts.co/nPxatndN

On track to report updated overall survival data for CAN-2409 from phase 2a clinical trials in pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC), expected in Q1 2025
Preparations for Biologics License Application (BLA) for CAN-2409 in prostate cancer underway, with submission expected in Q4 2026
The Company intends to present phase 3 clinical trial data from CAN-2409 in prostate cancer at upcoming scientific conferences
On track to report overall survival data in patients with recurrent high-grade glioma (rHGG) from ongoing phase 1b trial evaluating multiple doses of CAN-3110, expected in Q4 2025
The Company expects that its cash and cash equivalents of approximately $103M (unaudited) as of December 31, 2024, will be sufficient to fund its current operating plan into Q1 of 2027
NEEDHAM, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today highlighted recent successes across the Company's viral immunotherapy portfolio and provided an update on the Company’s cash position and upcoming 2025 milestones.

Stock rallied late and put in a hammer on the charts. More than average volume. Hopefully that is the tone going forward.

Hope we get some good news in 1st qtr on the two other readouts because as we may need it to stem the selling.  This is what sellers may be seizing upon:  Fast track, orphan status, etc., yet now they are saying FDA filing not until 4th qtr 2026.  Come on. Yeah waiting to line up publication of study and manufacturing.  

Company had some SEC filings today which apparently are explaining the dilution (which was announced in Dec) and I guess that is behind the drop today 

You are most welcome.

Thanks for posting this interview. Great info. Thank you.

Thanks for posting this interview. Great info. Thank you.

Great insights, thanks.

On Feuerstein: He is an influencer - he needs content so he will say something about everything that is up or down.

On Tak, check out his history at Flagship on top of his time at GSK. Im sure if they put the right amount of $$ on the table he will "switch his mind".

Remember prostate is notoriously
immunologically cold but CAN 2409 still worked...
So I believe it wil be even more effective in NSCLC and panc.

No question PBM is a heavyweight in small biotech investing. And of course as you mention Paul Manning who leads them is on the board at Candel and just sank a bunch of money into buying shares personally it seems.

For those who are not that familiar with CADL, this short talk with CEO Tak is a good primer:



If I had to pick a couple of things that were the least positive in that talk, I would say these would be it:
1) Around 5:40 mark, Tak talking about some clinical trial results are coming in the next qtr and "if several of these are positive".... - tough enough to have one study meet endpoints, so hoping for several positive results adds just a bit more anxiety to this. But hopefully past data dictates hope might be justified.
2) Although Tak mentions the path forward will probably involved BP in the form of partnerships, he seems to leave the U.S. market for CADL alone and talks about turning the company into a small Pharma. Although he worked for GSK and recognizes how BP has a much greater ability to drive sales, his mentioning of keeping the US for himself sends up red flags for me about GIA. I have seen that happen to so many small bios. Egos eventually doom the path forward.

Will be watching this closely.

CADL under $9

I think the key here is that PBM Capital is involved. I’m sure you checked out their investing history, but it’s impressive. Further, it looks like Paul Manning is directly involved.

As for Feuerstein, even broken clocks are right twice a day.

I notice that an old nemesis (in another stock years ago) Adam Feuerstein seems to be mostly bashing CADL. Not sure what his deal is. He has attacked CADL in relation to a lung cancer trial since it was not placebo controlled. But not really sure what his problem is here with prostate cancer.

I will say that there seems to be one point that he may have and that I find confusing myself. If anyone can better explain this one top line bullet point in the press release I would appreciate it:

Operator
05/09/2024 at 06:17 PM
This is a common misconception that this strip is common area, but it is actually a part of your lot and needs to be maintained the same as your lawn. No worries though, we are only recently sending out letters/citations about landscape maintenance so you do not need to worry about being fined in the meantime. For reference, it takes close to two months for us to issue fines following the initial citation, so you have plenty of time to make arrangements to accommodate this.

"14.5% relative improvement in DFS observed at 54 months for the CAN-2409 treatment arm compared to the placebo control arm"

I am not sure exactly what they are saying. I know AF also questions why specifically the 54 months. TIA

9.42

great

Triple avg volume so far today with an hour left.  

NICE rebound this morning how long will it last

Big insider purchase 2 days ago:

https://www.secform4.com/filings/1841387/0000950170-24-137889.htm

why not the ATM

Not very TAK ful
couldve been done a lot better I believe
now driftwood until the next readout.... Will be another opportunity

CADL: Hopefully, they get a CURE for all that bad PROSTATE stuff!!! (Had 1/3rd mine removed at the VA Hospital in Palo Alto few years back; NO joking!! And yet STILL must get up circa 4-times every night to PISS --- not fun. And even Orion's 'Mr. Monk' posted, if I'm not mistaken, that he HAS Prostate Cancer itself.)

$7 + 4% 3.3 million offerings at 5.99 sunk it down 50%. Need cash for last part of trial prostate...another $18 million 

Not ideal, that's for sure, but development stage, they don't have much of a choice. Did you check out the CMO? He was with Chimerix when it soared and was a solid Company. Left well before they fell apart.

The execs at Candel are solid. Whether they can get it done, is another story, of course.

Can't see a dip below 6, but seems to make sense to average down. Good luck, if you're in it.

thats not how you build trust Peter!

yikes

$CADL Doubled shares overnight with offering now has 60 million shares increased from 30 million shares. Expect this dilution will take it to below $4 level it was at prior to run up this week. Remember: $CADL has no revenues, at risk that it will never have a product and is losing close to 40 million $ per year. FDA trials take years and this will be a zombie stock. Watch for $3 to 4$ price level due to dilution.

7.5s..